The effect of coenzyme Q10 on sperm in infertile me
- Conditions
- OligospermiaN46.1Male Infertility.
- Registration Number
- IRCT20220809055653N1
- Lead Sponsor
- Bandare-abbas University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 30
Infertile couple with a male cause identified by the symptoms of idiopathic oligoasthenoteratospermia.
Definitive diagnosis of oligoasthenoteratospermia based on sperm count of less than 15 million per cc of semen, Sperm movement less than 32, Normal sperm morphology less than 4%.
Men age range 18-50 years old
Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm.
Patients with a history of reproductive system problems, including: undescended testicles, Klinefelter syndrome, hypogonadism, varicocele, cryptorchidism, and azoospermia and infection in reproductive tract and reproductive system
Patients with a history of inflammation and injury to the testicles that caused infertility
Patients with underlying disorder including: diabetes mellitus, hypothalamus and pituitary diseases and with thyroid gland problems, hypervitaminosis D and A, kidney stones and uncontrolled hypertension
History of allergy to the components of medicines: sperigen tablets and Q10 supplement
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sperm functional parameters (morphology, movement, number). Timepoint: Before intervention and during the study and the endpoint the study. Method of measurement: Para-clinical.;Permeability of sperm mitochondrial membrane. Timepoint: Before intervention and during the study and the endpoint the study. Method of measurement: Measuring the mitochondrial membrane potential (MMP).
- Secondary Outcome Measures
Name Time Method Breakage rate of sperm nuclear DNA. Timepoint: Before intervention and during the study and the endpoint the study. Method of measurement: SDFA kit.;Reactive oxygen species (ROS) level of semen liquid. Timepoint: Before intervention and during the study and the endpoint the study. Method of measurement: ROS kit.;Expression level of apoptosis genes: survivin (anti-apoptotic gene) and caspase 3 (apoptotic gene). Timepoint: Before intervention and during the study and the endpoint the study. Method of measurement: RT-PCR.